News

Video

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study

Author(s):

Ricardo D. Parrondo, MD

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

Related Videos
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Justin Kaner, MD
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Minoo Battiwalla, MD, MS, director, Blood Cancer Outcomes Research, Sarah Cannon Research Institute, TriStar Medical Group
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Related Content
Jorge Cortes, MD
October 17th 2024

Asciminib Yields Promising Efficacy vs SOC Agents in CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
October 16th 2024

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Armin Ghobadi, MD, of the Washington University School of Medicine
October 7th 2024

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

Helen Collins, MD, Enliven Therapeutics
October 7th 2024

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML